Proteomics Analysis Identified ASNS as a Novel Biomarker for Predicting Recurrence of Skull Base Chordoma.
asparagine synthetase
nomogram
proteomics
recurrence
skull base chordoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
06
2021
accepted:
17
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
The prognostic factors of skull base chordoma associated with outcomes of patients after surgery remain inadequately identified. This study was designed to identify a novel prognostic factor for patients with skull base chordoma. Using a proteomic technique, the tumor biomarkers that were upregulated in the rapid-recurrence group of chordoma were screened and then narrowed down by bioinformatic analysis. Finally one potential biomarker was chosen for validation by immunohistochemistry using tissue microarray (TMA). A total of 187 patients included in TMA were randomly divided into two cohorts, the training cohort included 93 patients and the validation cohort included 94 patients. Kaplan-Meier survival analysis was used to assess the patients' survival. Univariable and multivariable Cox regression analysis were used to identify prognostic factors predicting recurrence-free survival (RFS). CCK-8 assay, clonal formation assay and transwell assay were used to test the effect of asparagine synthetase (ASNS) on the proliferation, migration and invasion in chordoma cell lines. Among 146 upregulated proteins, ASNS was chosen as a potential prognostic biomarker after bioinformatics analysis. The H-scores of ASNS ranged from 106.27 to 239.58 in TMA. High expression of ASNS was correlated with shorter RFS in both the training cohort (p = 0.0093) and validation cohort (p < 0.001). Knockdown of ASNS by small interfering RNA (siRNA) inhibited the growth, colony formation, migration and invasion of chordoma cells This study indicates that high expression of ASNS is correlated with poor prognosis of patients with skull base chordoma. ASNS may be a useful prognostic factor for patients with skull base chordoma.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic factors of skull base chordoma associated with outcomes of patients after surgery remain inadequately identified. This study was designed to identify a novel prognostic factor for patients with skull base chordoma.
METHOD
METHODS
Using a proteomic technique, the tumor biomarkers that were upregulated in the rapid-recurrence group of chordoma were screened and then narrowed down by bioinformatic analysis. Finally one potential biomarker was chosen for validation by immunohistochemistry using tissue microarray (TMA). A total of 187 patients included in TMA were randomly divided into two cohorts, the training cohort included 93 patients and the validation cohort included 94 patients. Kaplan-Meier survival analysis was used to assess the patients' survival. Univariable and multivariable Cox regression analysis were used to identify prognostic factors predicting recurrence-free survival (RFS). CCK-8 assay, clonal formation assay and transwell assay were used to test the effect of asparagine synthetase (ASNS) on the proliferation, migration and invasion in chordoma cell lines.
RESULTS
RESULTS
Among 146 upregulated proteins, ASNS was chosen as a potential prognostic biomarker after bioinformatics analysis. The H-scores of ASNS ranged from 106.27 to 239.58 in TMA. High expression of ASNS was correlated with shorter RFS in both the training cohort (p = 0.0093) and validation cohort (p < 0.001). Knockdown of ASNS by small interfering RNA (siRNA) inhibited the growth, colony formation, migration and invasion of chordoma cells
CONCLUSION
CONCLUSIONS
This study indicates that high expression of ASNS is correlated with poor prognosis of patients with skull base chordoma. ASNS may be a useful prognostic factor for patients with skull base chordoma.
Identifiants
pubmed: 34540668
doi: 10.3389/fonc.2021.698497
pmc: PMC8440958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698497Informations de copyright
Copyright © 2021 Shen, Li, Xiong, Gui, Bai, Zhang and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Cancer. 2013 Jul 9;109(1):14-23
pubmed: 23764751
Nat Med. 2003 Aug;9(8):980
pubmed: 12894142
Biochem J. 1974 Jul;142(1):27-35
pubmed: 4216348
Biochem J. 2000 Oct 1;351(Pt 1):1-12
pubmed: 10998343
World Neurosurg. 2017 Jan;97:39-48
pubmed: 27671886
Cancer Res. 2007 Apr 1;67(7):3345-55
pubmed: 17409444
J Transl Med. 2020 Feb 13;18(1):77
pubmed: 32054505
Laryngoscope. 2014 May;124(5):1097-102
pubmed: 24122844
Am J Pathol. 2012 Mar;180(3):895-903
pubmed: 22245216
Nature. 2014 Sep 18;513(7518):382-7
pubmed: 25043054
Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98
pubmed: 9559053
Mol Cancer Ther. 2013 Oct;12(10):2157-66
pubmed: 23956056
Cancers (Basel). 2020 Apr 21;12(4):
pubmed: 32326232
Chem Biol Drug Des. 2014 Nov;84(5):578-84
pubmed: 24775638
J Neurosurg. 2007 Aug;107(2):319-24
pubmed: 17695386
Front Oncol. 2020 Apr 08;10:493
pubmed: 32322560
Cancer Genomics Proteomics. 2020 May-Jun;17(3):259-269
pubmed: 32345667
Cancer. 1973 Aug;32(2):410-20
pubmed: 4722921
Oncogene. 2004 May 27;23(25):4430-43
pubmed: 15077194
Lancet Oncol. 2015 Feb;16(2):e71-83
pubmed: 25638683
Am J Physiol. 1979 Jun;236(6):E746-53
pubmed: 35986
Mol Cancer Res. 2014 May;12(5):694-702
pubmed: 24505127
J Gastroenterol. 2019 Feb;54(2):131-140
pubmed: 29951927
J Pathol. 1993 Dec;171(4):253-5
pubmed: 8158454
BMC Genomics. 2015;16 Suppl 1:S8
pubmed: 25923178
Lancet Oncol. 2012 Feb;13(2):e69-76
pubmed: 22300861
J Neuropathol Exp Neurol. 2016 Feb;75(2):111-20
pubmed: 26733585
Oncogene. 2019 Oct;38(43):6881-6897
pubmed: 31406256
Nat Commun. 2020 Apr 7;11(1):1723
pubmed: 32265444
Biotechnol Appl Biochem. 2016 May;63(3):328-33
pubmed: 25858017